# EVALUATION OF A MONOCLONAL ANTIBODY

> **NIH NIH N01** · DYNPORT VACCINE COMPANY, LLC · 2022 · $843,463

## Abstract

The Biopharmaceutical Product Development Services program provides services to facilitate preclinical development of materials that are derived from biotechnology processes.

## Key facts

- **NIH application ID:** 10683485
- **Project number:** 272201600005I-0-759302200001-1
- **Recipient organization:** DYNPORT VACCINE COMPANY, LLC
- **Principal Investigator:** MARY KATE HART
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $843,463
- **Award type:** —
- **Project period:** 2022-07-20 → 2023-01-19

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10683485

## Citation

> US National Institutes of Health, RePORTER application 10683485, EVALUATION OF A MONOCLONAL ANTIBODY (272201600005I-0-759302200001-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10683485. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*